Sanjay Gandhi to Antibodies, Monoclonal
This is a "connection" page, showing publications Sanjay Gandhi has written about Antibodies, Monoclonal.
Connection Strength
0.530
-
Buse DC, Gandhi SK, Cohen JM, Ramirez-Campos V, Cloud B, Yang R, Cowan RP. Improvements across a range of patient-reported domains with fremanezumab treatment: results from a patient survey study. J Headache Pain. 2020 Sep 04; 21(1):109.
Score: 0.159
-
Lipton RB, Cohen JM, Gandhi SK, Yang R, Yeung PP, Buse DC. Effect of fremanezumab on quality of life and productivity in patients with chronic migraine. Neurology. 2020 08 18; 95(7):e878-e888.
Score: 0.158
-
Applegate RJ, Grabarczyk MA, Sane DC, Sacrinty MT, Goodin JE, Statonk GS, Baki TT, Gandhi SK, Kutcher MA, Little WC. PCI with and without abciximab after upstream eptifibatide use: outcomes in high-risk patients. J Invasive Cardiol. 2006 Dec; 18(12):604-13.
Score: 0.061
-
Applegate RJ, Upadhya B, Little WC, Xenakis M, Gandhi SK, Baki TT, Kahl FR, Kutcher MA. Late outcomes after intervention of vein grafts in diabetics with abciximab use. Int J Cardiol. 2006 Jul 28; 111(1):136-41.
Score: 0.057
-
Deliargyris EN, Upadhya B, Applegate RJ, Kutcher MA, Gandhi SK, Sane DC. Superior in-hospital and 30-day outcomes with abciximab versus eptifibatide: a contemporary analysis of 495 consecutive percutaneous coronary interventions. J Invasive Cardiol. 2004 Nov; 16(11):611-6.
Score: 0.053
-
Silberstein SD, Cohen JM, Yang R, Gandhi SK, Du E, Jann AE, Marmura MJ. Treatment benefit among migraine patients taking fremanezumab: results from a post hoc responder analysis of two placebo-controlled trials. J Headache Pain. 2021 Jan 07; 22(1):2.
Score: 0.041